# Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

> **NCT06196840** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Innostellar Biotherapeutics Co.,Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **GENETIC:** LX102 subretinal injection
- **BIOLOGICAL:** Aflibercept intravitreal injection

## Key facts

- **NCT ID:** NCT06196840
- **Lead sponsor:** Innostellar Biotherapeutics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-24
- **Primary completion:** 2025-06-24
- **Final completion:** 2029-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196840, "Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT06196840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*